U16 cell therapy for relapsed or refractory B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new cell therapy called U16 for people with certain types of B-cell lymphoma that have come back or not responded to previous treatments. The therapy uses your own immune cells to target and attack the cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a type of B-cell lymphoma that is CD20-positive, such as diffuse large B-cell lymphoma (DLBCL) or transformed follicular lymphoma.
- You have already tried at least 2 different treatments, or had a stem cell transplant using your own cells.
- Your lymphoma has come back or did not respond to the last treatment.
- You have at least one tumor that can be measured on a CT scan and is visible on a PET scan.
- You are generally in good health, with adequate blood counts and organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
This trial tests a new kind of immune cell therapy for people with certain types of lymphoma that have come back or not responded to previous treatments. The cells are made from your own blood and are designed to find and attack the cancer cells.
This trial is testing a new treatment called CD19x22 CAR T cells for people with certain types of B-cell lymphoma that have come back or not responded to other treatments. The therapy uses your own immune cells, which are modified in a lab to better attack the cancer.
This trial tests a new type of personalized cell therapy (CAR-T) for adults with B-cell acute lymphoblastic leukemia or B-cell lymphoma that has returned or not responded to standard treatments. The therapy uses your own immune cells to attack cancer cells.
This trial tests a new treatment using your own immune cells, called CAR T cells, that are specially made to find and attack cancer cells in B-cell lymphoma. It may help if your lymphoma has come back or has not gone away after other treatments.
This trial tests a new cell therapy (called RJMty19) for people with B-cell lymphoma that has returned or not responded to standard treatments. The therapy aims to find and attack cancer cells.
Hear when a new Relapsed or Refractory Non-Hodgkin's Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.